Navigation Links
Docetaxel in Medical News

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

ORLANDO - When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cance...

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

DENVER and SAN CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior antitumor activity...

Will The Combination Of Calcitriol and Docetaxel Work ?

Researchers from Canada, United States and Europe are registering men with advanced prostate cancer //for a study involving a treatment that combines chemotherapy with high-dose of Calcitriol, a naturally occurring active form of vitamin D. This clinical trial will test whether specially formul...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...of its human monoclonal antibody adecatumumab with docetaxel in patients with metastatic breast cancer. The trial demonstrated that combining adecatumumab with docetaxel was feasible, with clinically manageable diarrhea ... trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic brea...

Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations

... Poster Discussion Presentation #1199.10. (8) LUME-Lung 1: BIBF 1120 Plus docetaxel as Compared to Placebo Plus docetaxel in 2nd Line NSCLC. Available at: http://clinicaltrials.gov/ct2/show/NCT0080...

Advanced targeted therapies effective as first-line treatment for lung cancer

...at 2:30 pm PT in Moscone West, Room 2001-2005, Level 2. VANDETANIB PLUS docetaxel VERSUS docetaxel AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CAN...

AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer

...rolled study evaluating the combination of vandetanib 100mg once daily plus docetaxel versus docetaxel alone in patients with locally advanced or metastatic NSCLC, treated with o...

Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting

...on: Aug. 4, 2009, 1:30 p.m. PDT Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) +/- enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) PD9.1.1: Poster Discussi...

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer

...xavar plus gemcitabine or capecitabine in the first- or second-line setting following progression on bevacizumab, and a trial to evaluate Nexavar plus docetaxel and/or letrozole in the first-line setting. About Breast Cancer Breast cancer was the most commonly diagnosed cancer among women worl...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

...ministration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of DOXIL(R) (doxorubicin HCI liposome injection) and docetaxel did not provide a sufficient benefit-risk profile for the treatment of women with locally advanced or metastatic breast cancer. Women with lo...
Docetaxel in Medical Technology

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

-Preliminary Data from This Trial to be Presented at ASCO- -First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment- TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium - MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P)...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

-No Metastatic Lesions Were Detectable After Combination Therapy Treatment- -Survival Time More Than Doubled in Animals Treated with Combination Therapy- -Established Tumors Regressed by 50% After Combination Therapy Treatment- SAN DIEGO and TUSTIN, Calif., April...

Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda(R) have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8. Two of the abstracts include data from the X...

Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8. Two of the abstracts include data from the XeNA...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...tate cancer showing a median survival in patients treated with OGX-011 plus docetaxel of 23.8 months compared to 16.9 months for patients treated with docetaxel alone. OncoGenex reported that OGX-427 was well tolerated as a mono...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmac...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmac...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... - 71% Objective Tumor Response in Combination with docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combinat... In the Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients, enrollment of the planned 46 pat...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

..., demonstrating that the addition of vandetanib to docetaxel resulted in a statistically significant improvemen...valuating the combination of vandetanib 100mg with docetaxel versus docetaxel alone. The study enrolled 1391 patients previously...
Docetaxel in Biological News

TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer

...erable antitumor activity both with TG2 siRNA alone and in combination with docetaxel chemotherapy. The combination therapy of TG2 siRNA with docetaxel reduced tumor weight by 86 percent, proving to have the greatest efficacy c...

Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer

...f the disease). Before surgery they received four cycles of epirubicin/cyclophosphamide (EC) and were then randomised to receive either four cycles of docetaxel (D) or four cycles of D-capecitabine (DX), or a combination of both D and DX, or four cycles of D followed by four cycles of DX. Women with HER2-posit...

New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients

... We then randomised them to either four cycles of docetaxel alone, four cycles of simultaneous docetaxel and capecitabine, or four cycles of docetaxel followed by four cycles of capecitabine. If capec...

Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial

...with mice in the control groups. Combining the FAK-silencing liposome with docetaxel boosted tumor weight reduction to the 94-98 percent range. These res...lts also held up in experiments with ovarian cancer cell lines resistant to docetaxel and to the chemotherapy drug cisplatin. The FAK-silencing liposome and...
Docetaxel in Biological Technology

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) via the special protocol assessment process (SPA) on an amendment to the design ...

Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting

CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) today announced updated clinical results from its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers. The principal investigator for the trial is Professor Harde...

Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting

CALGARY, Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers. Prof. Hardev Pandha of the Royal Surrey...

Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract entitled "A Phase I Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel in Patients with Advanced Malignancies" will be available in...

Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

-Data Update Shows 71% of Evaluable Patients in the Trial's First Stage Achieved Objective Tumor Responses- -Patient Enrollment is Open in the Trial's Second Stage- TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cli...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ...

OncoGenex Reports Second Quarter 2009 Financial Results

...1 in combination with docetaxel compared to docetaxel alone. The median overall survival in patients ...e cancer who were treated with OGX-011 plus docetaxel in a randomized phase 2 trial was 23.8 months comp...ed to 16.9 months for patients treated with docetaxel alone -- a 6.9 month observed survival adva...

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

...is gift has been provided by sanofi-aventis U.S. to be used for scientific purposes as defined and overseen by the NIH. The donation of three drugs - docetaxel (Taxotere(R)), oxaliplatin injection (Eloxatin(R)) and enoxaparin sodium injection (Lovenox(R)) - will be made over the course of one year. "...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

...d efficacy and safety data demonstrated that picoplatin in combination with docetaxel and prednisone is active as first-line therapy for metastatic CRPC as demon...tered every three weeks for up to 10 cycles concurrently with full doses of docetaxel and prednisone, the standard treatment for CRPC. In addition, no neurotoxi...

Micromet Closes $80.5 Million Public Offering of Common Stock

... colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmac...
Other Tags
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The inaugural ... Latinos demonstrate their passion for protecting our environment and ... in the Southwest, will go on hiking or camping ... to show their support for permanently protecting our land, ... sharing the Latino community’s perspective on the environment like ...
(Date:7/27/2014)... North American security and surveillance radar market under defense ... it is expected to reach $2030 million by 2019 ... factors that influence a country’s expenditure on radars. It ... expenditure. The report also throws light on the leading ... overview of the companies, it focuses on their financial ...
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with ... can be manufactured either through the separation from crude ... Linear alpha olefin (alkene) 1-Butene is a versatile chemical ... important chemicals such as linear light density polyethylene (LLDP), ... 1-Butene market is extremely competitive. The market has several ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Although ... Australia is restricted to two companies, heavy government ... IBISWorld industry analyst Spencer Little, “Demand for cigarettes ... to rising health concerns, frequent anti-smoking campaigns, increasing ... industry revenue is estimated to fall at a ...
Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
(Date:7/25/2014)... Ravi Birla, associate professor of biomedical engineering at ... textbook on tissue engineering and artificial organ development., ... a comprehensive guide to entering into the field ... and professor of biomedical engineering at UH, served ... said that while there are other published books ...
(Date:7/25/2014)... which is derived from diffusion tensor imaging (DTI), ... such as the corticospinal tract, the rubrospinal tract, ... tract is known to be a major neural ... Several studies have reported on injury of the ... studies have demonstrated recovery of a corticospinal tract ...
(Date:7/25/2014)... Biometrics industry expands and becomes ... technology for online & commerce payments while seeking security ... GOOG ), LifeLock Inc. (NYSE: LOCK ... Inc. (NASDAQ: AAPL ) and Fortinet Inc. ... biometric authentication company focused on the growing m-commerce market, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
Other Contents